beta-Alethine (
beta-alanyl-cysteamine disulfide) exhibits striking
biological activities in diverse systems. At an optimum of about 10 ng/ml,
beta-alethine (a) adapts murine liver cells to culture (53 colonies/10(6) cells versus none in controls), (b) delays aging of human IMR-90 fetal lung fibroblasts (102 population doubling levels versus 47 in controls, producing 3 x 10(16) greater biomass), and (c) markedly stimulates antibody-producing plaque-forming cells from murine splenocytes (16,875/10(6) cells versus 55/10(6) cells in controls) or human peripheral blood leukocytes (1826/10(6) cells versus 0/10(6) cells in controls). Early interventions with
beta-alethine (1 ng/kg to 100 micrograms/kg) successfully treat
NS-1 myeloma in a syngeneic murine
tumor model (NS-1 myeloma). Although there are indications in this model that
beta-alethine is also effective when intervention is late,
beta-alethine is ineffective in an allogeneic murine
melanoma model (Cloudman S-91
melanoma). It is inferred that
beta-alethine enhances cellular phenotypic expression, function, and vitality in diverse
biological systems and may treat certain types of
neoplasia. Because atomic spacings between the
amide moieties in
beta-alethine are the same as in the differentiating agent hexamethylene-bis-
acetamide and because the radioprotectors
WR 2721 and
WR 1065 lack only the carbonyl
oxygen of the
thiol form (beta-aletheine),
biological activities already reported for these compounds are compared with those presented herein for
beta-alethine. Although these comparisons have not been made in the same systems, the tentative conclusion is that the
amide moieties of
beta-alethine may be critical to its potency and lack of obvious toxicity in cell culture and animal models.